Aerovate Therapeutics Reports Q2 2024 Results
Ticker: JBIO · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1798749
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: AVTE
TL;DR
Aerovate Therapeutics (AVTE) Q2 loss $28.6M, assets $287.6M, liabilities $1.68M.
AI Summary
Aerovate Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2024. The company had total assets of $287.6 million and total liabilities of $1.68 million as of June 30, 2024. For the three months ended June 30, 2024, the company reported a net loss of $28.6 million.
Why It Matters
This filing provides insight into Aerovate Therapeutics' financial health and operational performance, which is crucial for investors and stakeholders evaluating the company's progress in developing its pharmaceutical products.
Risk Assessment
Risk Level: medium — The company reported a net loss, indicating ongoing expenses without corresponding revenue, which is typical for development-stage biopharmaceutical companies but carries inherent financial risk.
Key Numbers
- $287.6M — Total Assets (As of June 30, 2024)
- $1.68M — Total Liabilities (As of June 30, 2024)
- $28.6M — Net Loss (For the three months ended June 30, 2024)
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Filer of the 10-Q report
- June 30, 2024 (date) — End of the reporting period
- $287.6 million (dollar_amount) — Total assets as of June 30, 2024
- $1.68 million (dollar_amount) — Total liabilities as of June 30, 2024
- $28.6 million (dollar_amount) — Net loss for the three months ended June 30, 2024
FAQ
What was Aerovate Therapeutics' net loss for the three months ended June 30, 2024?
Aerovate Therapeutics reported a net loss of $28.6 million for the three months ended June 30, 2024.
What were the total assets of Aerovate Therapeutics as of June 30, 2024?
As of June 30, 2024, Aerovate Therapeutics had total assets of $287.6 million.
What were the total liabilities of Aerovate Therapeutics as of June 30, 2024?
Aerovate Therapeutics reported total liabilities of $1.68 million as of June 30, 2024.
What is the fiscal year end for Aerovate Therapeutics?
Aerovate Therapeutics' fiscal year ends on December 31.
What is the primary business of Aerovate Therapeutics?
Aerovate Therapeutics is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 4,530 words · 18 min read · ~15 pages · Grade level 18.3 · Accepted 2024-08-12 16:31:10
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share AVTE The Nasdaq Global Ma
Filing Documents
- tmb-20240630x10q.htm (10-Q) — 1902KB
- tmb-20240630xex31d1.htm (EX-31.1) — 9KB
- tmb-20240630xex31d2.htm (EX-31.2) — 9KB
- tmb-20240630xex32d1.htm (EX-32.1) — 5KB
- tmb-20240630xex32d2.htm (EX-32.2) — 5KB
- 0001798749-24-000049.txt ( ) — 7285KB
- tmb-20240630.xsd (EX-101.SCH) — 33KB
- tmb-20240630_cal.xml (EX-101.CAL) — 48KB
- tmb-20240630_def.xml (EX-101.DEF) — 119KB
- tmb-20240630_lab.xml (EX-101.LAB) — 305KB
- tmb-20240630_pre.xml (EX-101.PRE) — 244KB
- tmb-20240630x10q_htm.xml (XML) — 1544KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets 7 Condensed Consolidated Statements of Operations and Comprehensive Loss 8 Condensed Consolidated Statements of Stockholders' Equity 9 Condensed Consolidated Statements of Cash Flows 10 Notes to Unaudited Condensed Consolidated Financial Statements 11 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 29 PART II. OTHER INFORMATION 29 Item 1.
Legal Proceedings
Legal Proceedings 29 Item 1A.
Risk Factors
Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 3. Defaults Upon Senior Securities 74 Item 4. Mine Safety Disclosures 74 Item 5. Other Information 74 Item 6. Exhibits 75
Signatures
Signatures 76 2 Table of Contents SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following: We may not be successful in identifying and implementing any strategic transaction and any strategic transactions that we may consummate in the future could have negative consequences. Even if we successfully consummate any transaction from our strategic assessment, including, but not limited to, a merger, acquisition or business combination, we may fail to realize all of the anticipated benefits of the transaction, those benefits may take longer to realize than expected, or we may encounter integration difficulties. If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks. Our board of directors may decide to pursue a dissolution and liquidation instead of a strategic transaction. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. We are a biopharmaceutical company with a limited operating history. We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability. We have no products approved for commercial sale and have not generated any revenue from product sales. Should we resume development of AV-101 or any other product candidates, our business would be entirely dependent on the successful development, regulatory approval and commercialization of such product candidates. The results of earlier studies and trials may not be predictive of future trial results. We have experienced
-FINANCIAL INFORMATION
PART I-FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. Aerovate Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 31,069 $ 23,491 Short-term investments 73,133 98,948 Prepaid expenses and other current assets 6,558 1,793 Total current assets 110,760 124,232 Property and equipment, net 232 288 Operating lease right-of-use assets 621 614 Other long-term assets 81 2,284 Total assets $ 111,694 $ 127,418 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,179 $ 2,396 Accrued and other current liabilities 12,366 14,821 Operating lease liabilities 475 420 Total current liabilities 17,020 17,637 Operating lease liabilities, net of current portion 206 255 Other liabilities 70 70 Total liabilities 17,296 17,962 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.0001 par value; 150,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 28,854,750 and 27,762,703 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 3 Additional paid-in capital 305,863 272,640 Accumulated other comprehensive (loss) income ( 83 ) 237 Accumulated deficit ( 211,385 ) ( 163,424 ) Total stockholders' equity 94,398 109,456 Total liabilities and stockholders' equity $ 111,694 $ 127,418 See accompanying notes to unaudited interim condensed consolidated financial statements. 7 Table of Contents Aerovate Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousan